Eli Lilly (LLY) Acquires Centessa Pharmaceuticals to Advance Orexin Receptor 2 Agonists
1 min read
The story
Eli Lilly has agreed to acquire Centessa Pharmaceuticals, a UK-based clinical-stage biotech, in a move that brings OX2R agonist assets into Lilly's neuroscience pipeline. Orexin receptor 2 agonists are a mechanistically novel class targeting narcolepsy and excessive daytime sleepiness — a space where Takeda's solriamfetol and Jazz Pharmaceuticals' Xywav compete but where no oral OX2R agonist has yet reached the market. No deal price has been publicly confirmed in this initial headline.
Lilly arrives at this deal off a period of exceptional top-line momentum: FY2025 revenues reached $65.2B, up 44.7% year-over-year, driven heavily by tirzepatide (Mounjaro/Zepbound). Net margin stood at 31.7% and diluted EPS came in at $22.95, giving Lilly the financial firepower to pursue bolt-on acquisitions without straining its balance sheet. Adding Centessa diversifies Lilly away from near-total dependence on GLP-1 revenues.
The strategic rationale is clear: OX2R agonists represent one of the most watched emerging CNS mechanisms, with TAM estimates in narcolepsy alone running into several billion dollars. Competitors including Takeda and Jazz have CNS exposure, but a successful oral OX2R agonist would be a first-in-class product. Centessa's lead asset, previously called ORX750, was in early-to-mid clinical development — de-risked enough to be attractive but early enough that Lilly could shape the clinical program.
The key unknowns are deal price, milestone structure, and how far Centessa's OX2R data actually extend. If the acquisition comes at a rich premium to Centessa's last traded value, markets may react negatively to capital deployment. If the price is reasonable and Phase 2 data are compelling, the deal could be viewed as a disciplined, high-optionality add-on for a company with the cash flow to absorb execution risk.
What to watch: official deal terms and any disclosed clinical data package; analyst reaction to the strategic fit versus GLP-1 concentration risk; and whether Lilly guides for any revenue contribution timeline from the neuroscience pipeline in upcoming earnings calls.
The case — both sides
Lilly's 44.7% revenue growth and 31.7% net margin give it the financial capacity to absorb an early-stage CNS bet while OX2R agonists, if successful, represent a first-in-class oral treatment for narcolepsy with multi-billion-dollar TAM potential entirely additive to the GLP-1 franchise.
Without disclosed deal terms or confirmed Phase 2 data, investors cannot assess whether Lilly is overpaying for a pre-commercial asset in a mechanism that has seen prior clinical failures, and the GLP-1 franchise already commands a premium multiple that leaves little margin for capital-allocation missteps.
The house read
Two-sidedLLY's Centessa acquisition adds a novel OX2R pipeline to an already high-growth platform — the question is whether the deal price and clinical stage justify the capital outlay or dilute near-term returns.
Wrong ifA high acquisition premium with only early-stage clinical data would signal capital misallocation; any Phase 2 setback for the OX2R program post-close would be a direct negative for the rationale of the deal.
Published read · research, not advice